ELUT
Elutia Inc.
There isn't enough reported data to score ELUT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ELUT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
ELUT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ELUT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.8x | $0.94 | +7.2% |
| Current | 0.8x | $0.88 | — |
| Fair | 1x | $1.18 | +34% |
| Expensive | 1.2x | $1.43 | +62% |
Historical ranges are pointers, not guarantees.
ELUT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ELUT Forward outlook
There aren't enough analyst estimates for ELUT to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ELUT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.15 | +$2.07 |
| Q2 2026 | $1.00 | +$2.06 |
| Q1 2026 | $0.91 | +$2.84 |
| Q4 2025 | $0.87 | +$3.34 |
| Q3 2025 | -$0.92 | +$1.65 |
| Q2 2025 | -$1.06 | +$1.75 |
| Q1 2025 | -$1.93 | +$0.40 |
| Q4 2024 | -$2.47 | -$0.40 |
ELUT has returned to profit: it earned $1.15 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ELUT on earnings, with more consistent year-over-year improvement.
ELUT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -66% |
| Q2 2026 | $2.4M | -61% |
| Q1 2026 | $3.1M | -48% |
| Q4 2025 | $3.3M | -40% |
| Q3 2025 | $3.3M | -44% |
| Q2 2025 | $6.3M | -0.4% |
| Q1 2025 | $6M | -9.9% |
| Q4 2024 | $5.5M | -6.9% |
ELUT's revenue has slid since its 2023 peak: $1M last quarter, down 66% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -607% | -450 points |
| Q2 2026 | -328% | -170 points |
| Q1 2026 | -204% | -73 points |
| Q4 2025 | -201% | -46 points |
| Q3 2025 | -157% | +16 points |
| Q2 2025 | -158% | -22 points |
| Q1 2025 | -131% | -4.7 points |
| Q4 2024 | -154% | -9.4 points |
ELUT's operating margin was −607% last quarter, down 450 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ELUT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ELUT on profitability, with a higher operating margin.
ELUT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.2M | -$4.7M |
| Q2 2026 | -$8.6M | -$210K |
| Q1 2026 | -$8.3M | +$869K |
| Q4 2025 | -$25.7M | -$13.3M |
| Q3 2025 | -$3.5M | +$457K |
| Q2 2025 | -$8.3M | -$4M |
| Q1 2025 | -$9.2M | -$6.5M |
| Q4 2024 | -$12.4M | -$3.3M |
ELUT has burned cash in almost every quarter: −$51M over the past year, against −$33M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ELUT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ELUT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +3.3M shares |
| 1 year | +1.2% | +581K shares |
| 3 years | +179% | +30.5M shares |
| 5 years | +364% | +37.3M shares |
ELUT has 48M diluted shares, up 1.2% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ELUT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ELUT Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ELUT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.8 | Neutral |
| Stochastic | 47.7 | Neutral |
ELUT's weekly RSI is 48 (neutral) and its Stochastic is 48 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ELUT PE vs Healthcare Sector
| Metric | ELUT | Sector median | Relative |
|---|---|---|---|
| PE | 0.8x | 26x | 97% below |
| PE % | 3 | 33 | 30 pts below |
ELUT has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ELUT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.83 | 6% above |
| 20 week MA | $0.87 | 1.1% above |
| 50 week MA | $0.93 | 5.4% below |
| 100 week MA | $1.53 | 42% below |
| 200 week MA | $2.24 | 61% below |
ELUT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 61% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ELUT on trend strength, trading above more of its moving averages.
ELUT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $12.6 | -7.2% |
| 2021 | $12.6 | $6.67 | -47% |
| 2022 | $6.67 | $4.10 | -39% |
| 2023 | $4.10 | $2.16 | -47% |
| 2024 | $2.16 | $3.94 | +82% |
| 2025 | $3.94 | $0.54 | -86% |
| 2026 YTD | $0.54 | $0.88 | +63% |
ELUT has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.